Highlights 

  • Seven startups recognized for advancing therapies across reproductive, chronic, and mental health. 
  • Women’s health receives only 15% of VC funding and 5% of global healthcare R&D. 
  • The companies assessed clinical trials, IP portfolio, financing, and R&D progress. 

Clarivate Plc (NYSE:CLVT) released its Companies to Watch report, Rediscovering Women’s Health, highlighting seven startups driving innovation in reproductive care, chronic disease, and mental health. Leveraging proprietary data and expert analysis, the report identifies organizations addressing unmet medical needs, financing activity, and R&D momentum in the women’s health sector. 

Despite representing roughly half of the global population, women remain underrepresented in clinical research and healthcare investment. Currently, women’s health accounts for only 15% of venture capital funding and 5% of global healthcare R&D. The report emphasizes companies developing inclusive research, novel therapies, and solutions targeting female-specific conditions such as early menopause, polycystic ovary syndrome (PCOS), and endometriosis, which also affect broader health outcomes including cardiovascular disease and dementia. 

Management Commentary 

Anne Lecocq, SVP and GM, R&D, Life Sciences & Healthcare, Clarivate, stated, “Women’s health is no longer being defined solely by reproductive care; it’s being reframed through a broader lens that recognizes how biological and social factors shape outcomes across every therapeutic area. This shift marks a pivotal moment for the industry, as data-driven innovation and inclusive research begin to translate into more equitable care and better health outcomes for women worldwide. By spotlighting organizations driving this change, the Companies to Watch report underscores how scientific insight and investment can work together to close persistent gaps and advance women’s health globally.” 

Agnès Arbat, MD, Co-Founder and CEO, Oxolife, added, “The next era of women’s health innovation will be defined by science that recognizes women’s unique biology as the foundation for discovery. Across the industry, we’re seeing a long-overdue shift toward inclusive research and smarter, more targeted therapies that can truly transform outcomes for women.” 

Startups Featured 

The seven companies highlighted include: 

  • Daré Bioscience (USA): Developing evidence-based solutions across contraception, reproductive, and menopausal health. 
  • Freya™ Biosciences (Denmark/USA): Leveraging DYSCOVER™ multi-omics platform for microbial immunotherapies targeting chronic reproductive inflammation. 
  • Gesynta Pharma (Sweden): Developing non-hormonal therapies for endometriosis and chronic pain. 
  • Granata Bio Corporation (USA): Advancing fertility treatments to expand access and improve outcomes. 
  • Hope Medicine (Mainland China): Developing endocrine, cardiovascular, and metabolic therapies, including lead asset HMI-115. 
  • Oxolife (Spain): Focusing on embryo implantation, ovulation restoration, metabolic health, and pregnancy outcomes. 
  • Reunion Neurosciences (USA): Developing psychedelic-inspired therapies for postpartum depression and adjustment disorders. 

About Clarivate 

Clarivate provides global data, insights, analytics, workflow solutions, and expert services across Academia & Government, Intellectual Property, and Life Sciences & Healthcare.